AA
RNAC icon

ALPS Advisors’s Cartesian Therapeutics RNAC Stock Holding History

ALPS Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-19,392
Closed -$256K – 1056
2025
Q1 		$256K Sell
19,392
-1,158
-6% -$20.7K ﹤0.01% 945
2024
Q4 		$368K Buy
+20,550
New +$416K ﹤0.01% 748
2021
Q4 		– Sell
-4,702
Closed -$587K – 962
2021
Q3 		$587K Sell
4,702
-268
-5% -$32.4K 0.01% 482
2021
Q2 		$623K Sell
4,970
-1,545
-24% -$184K 0.01% 490
2021
Q1 		$884K Buy
6,515
+120
+2% +$14.9K 0.01% 411
2020
Q4 		$581K Buy
+6,395
New +$555K 0.01% 479
2018
Q2 		– Sell
-999
Closed -$305K – 965
2018
Q1 		$305K Buy
999
+174
+21% +$49.6K ﹤0.01% 815
2017
Q4 		$243K Buy
+825
New +$360K ﹤0.01% 776

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ALPS Advisors's RNAC Position: Q2 2025 in Review

ALPS Advisors sold out of Cartesian Therapeutics (RNAC) in Q2 2025, closing a stake of 19,392 shares — an estimated $256K sold.

ALPS Advisors first reported a position in RNAC in Q4 2017 and held it in 8 quarters. The position peaked at $884K in Q1 2021. 66 funds tracked by Wall St. Rank hold RNAC as of Q2 2025.

  • ALPS Advisors reported no remaining Cartesian Therapeutics position as of Q2 2025 after selling out during the quarter.
  • ALPS Advisors sold 19,392 Cartesian Therapeutics shares in Q2 2025, an estimated $256K.
  • ALPS Advisors first reported a position in Cartesian Therapeutics in Q4 2017 and held it in 8 quarters.
  • ALPS Advisors's Cartesian Therapeutics position peaked at $884K in Q1 2021.
  • 66 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2025.

Based on ALPS Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.